Search

Being responsive to customers requires businesses to be fast and right. If the business is right, the customer gets what he/she needs. Value depends on how fast the response is delivered. Topics include an explanation and examples of customer responsiveness and the four key elements of customer responsiveness, and how organizations transform.

The article reports that the HER2CLIMB Trial Results Confirm Survival Benefit with Tucatinib in HER2- Positive Breast Cancer. Topics discussed include the findings were presented at the American Society of Clinical Oncology 2021 virtual annual meeting by lead investigator Giuseppe Curigliano, Associate Professor, Medical Oncology, University of Milano, Italy; and The trial met all primary and secondary end points at the time of the primary analysis.

The article focuses on the Practices for Optimizing Opioid Therapy in Patients with Cancer Pain. Topics discussed include the 2021 Hematology/Oncology Pharmacy Association annual conference, a panel of oncology pharmacists presented a stewardship approach to opioid therapy; and focusing on the safe use of opioid analgesics in patients with cancer, who are significantly more likely to receive opioid therapy than individuals without a history of cancer.

The article discusses that the Axicabtagene ciloleucel demonstrated significant clinical benefit, with high overall and complete response rates and a manageable safety profile," stated lead investigator Sattva S. Neelapu, MD, Deputy Chair, Department of Lymphoma/Myeloma. It mentions that the study also provides new insights into the pharmacology of CART-cell therapy for patients exposed to fewer prior therapies.

The article informs that enrollment in clinical trials is vital for the advancement of knowledge and improvement of patient outcomes, but few adults participate in cancer clinical trials. Topics include racial disparities exist within enrollment in clinical trials in oncology; and proportion of enrollment by age showed that black patients diagnosed in their twenties.

The article offers information on the standard of care for newly diagnosed multiple myeloma. It discusses that dyspnea, hypertension, heart failure, and acute kidney injury were more common in the carfilzomib (Kyprolis) with lenalidomide (Revlimid) and dexamethasone group, whereas neurologic toxicity and peripheral neuropathy were significantly higher in patients receiving bortezomib (Velcade), lenalidomide, and dexamethasone.

The article reports that immune checkpoint inhibitor nivolumab (Opdivo) appears to be effective in pediatric patients with hypermutant or ultra-hypermutant cancers, a study reported by American Society of Clinical Oncology 2021 annual meeting. Topics include findings contrast with previous pediatric studies of immune checkpoint inhibitors; and context of replication repair deficiency (RRD) and hypermutation, immune checkpoint inhibition therapy.

The article reports that rapid adoption of Food & Drug Administration (FDA)-approved biosimilars is feasible, measurable, and scalable and pharmacists should lead the charge. Topics include results of a pharmacy-driven intervention showed a statistically significant increase in biosimilar adoption; and pharmacy-based substitution approach allows providers to focus on front-end patient care instead of the back-end medication substitution process.

The article discusses findings of a study presented during the American Society of Clinical Oncology 2021 virtual annual meeting which identified a significant age difference between African-American and non–African-American men with respect to high genomic risk. According to lead study investigator Kosj Yamoah, African-American men have a higher incidence of prostate cancer and are more likely to die from the disease compared with their white counterparts.

The article informs that data presented at the virtual 2021 American Society of Clinical Oncology Quality Care Symposium has revealed that utilization of the biosimilar trastuzumabanns is trending in the right direction. According to lead study investigator Catherine M. Lockhart, trastuzumab biosimilars are turning out to be a bigger success story than it has been seen with all the other biosimilar classes in the U.S.

The article discusses a research presented at the virtual 2021 American Society of Clinical Oncology Quality Care Symposium to lead better healthcare utilization and higher quality end-of-life care. It also discusses the ability of patients to formalize their limits to treatment after a single advance care planning discussion. It is noted that Aliya Gessling and her team plan to lower risk and utilize a Patient Aligned Care Team to increase participation in telehealth visits.

The article informs that data presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Quality Care Symposium has revealed that nearly 300 clinical oncologists identified major knowledge deficits on basic features of biosimilars. According to lead study investigator John Devin Peipert, there is a great deal of opportunity for new educational interventions or quality improvement programs for oncologists.

The article presents results from a clinical trial presented during the American Society of Clinical Oncology 2021 virtual annual meeting, aspacytarabine, a prodrug of cytarabine, appears safe and effective as first-line therapy for patients with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. Topics include how AML chemotherapy backbone for challenging patient population; and patients who achieved omplete response (CR) were minimal residual disease (MRD)-negative.

The article focuses on the New Opportunities in Clinical Trials and Drug Development After COVID-19. Topics discussed include the optimize clinical trials for the future, Dr. Finnes said, providers must investigate new and inventive care-delivery methods; and this means continuing many of the remote practices that were instituted during the pandemic.

The article discusses that Immunotherapy Continues to Transform the Treatment Landscape for Advanced number of drugs approved by the FDA for non– small-cell lung cancer (NSCLC). Topics discussed include the results showed a significant improvement in the median duration of overall survival with the dual immunotherapy plus chemotherapy arm; and the results showed that first-line treatment with the combination of nivolumab plus ipilimumab led to a longer overall survival.

The article focuses on the Updates on the Use of Anticoagulants for Cancer-Associated Thromboembolism. Topics discussed include Thrombosis in patients with cancer may be a relatively common complication, but the treatment of venous thromboembolism (VTE) in this patient population is anything but simple; and patients with cancer have up to 6 times increased risk for recurrent VTE compared with patients without cancer.

The article discusses that the new step-up dosing schedule with glofitamab, an investigational T-cell engaging bispecific antibody, has demonstrated strong clinical activity, with high complete response rates in patients with hard-to-treat relapsed or refractory non-Hodgkin lymphoma (NHL). It mentions that the study included pretreatment with obinutuzumab (Gazyva), which was intended to reduce cytokine release syndrome (CRS) and to enable an increasing dosing schedule.

The article discusses that the single-agent mosunetuzumab is a safe and clinically promising chemotherapy-free therapy for elderly and unfit patients with untreated diffuse large B-cell lymphoma (DLBCL). It mentions that the Mosunetuzumab is a fully humanized immunoglobulin G1 anti-CD20 and anti-CD3 bispecific antibody that redirects T-cells to engage and eliminate malignant B-cells.